Special Populations in Pivotal Clinical Trials: Eligibility and Supporting Evidence for Exclusion in <scp>EMA</scp> ‐Authorised Medicines

Maja J. Jørgensen, Débora D. Gräf, Christine E. Hallgreen

Open source

DOI
10.1002/cpt.70475
Published
2026-09-04
Container
Clinical Pharmacology &amp; Therapeutics
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/cpt.70475,
  title = {Special Populations in Pivotal Clinical Trials: Eligibility and Supporting Evidence for Exclusion in
                    <scp>EMA</scp>
                    ‐Authorised Medicines},
  author = {Maja J. Jørgensen and Débora D. Gräf and Christine E. Hallgreen},
  year = {2026},
  journal = {Clinical Pharmacology \&amp; Therapeutics},
  doi = {10.1002/cpt.70475},
  url = {https://doi.org/10.1002/cpt.70475}
}

RIS

TY  - JOUR
TI  - Special Populations in Pivotal Clinical Trials: Eligibility and Supporting Evidence for Exclusion in
                    <scp>EMA</scp>
                    ‐Authorised Medicines
AU  - Maja J. Jørgensen
AU  - Débora D. Gräf
AU  - Christine E. Hallgreen
PY  - 2026
JO  - Clinical Pharmacology &amp; Therapeutics
DO  - 10.1002/cpt.70475
UR  - https://doi.org/10.1002/cpt.70475
ER  - 

APA

Jørgensen, M. J., Gräf, D. D., & Hallgreen, C. E. (2026). Special Populations in Pivotal Clinical Trials: Eligibility and Supporting Evidence for Exclusion in <scp>EMA</scp> ‐Authorised Medicines. Clinical Pharmacology &amp; Therapeutics. https://doi.org/10.1002/cpt.70475

Source records